Nonsteroidal Selective Androgen Receptor Modulator Ostarine^™ in Cancer Cachexia

• Stephens NA , SkipworthRJ, FearonKC: Cachexia, survival and the acute phase response.Curr. Opin. Support. Palliat. Care2(4), 267–274 (2008).
   PubMedGoogle Scholar
• Fearon KC , VossAC, HusteadDS, Cancer Cachexia Study Group: Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis.Am. J. Clin. Nutr.83(6), 1345–1350 (2006).
   PubMed Web of Science ®Google Scholar
• Skipworth RJ , StewartGD, DejongCH, PrestonT, FearonKC: Pathophysiology of cancer cachexia: much more than host–tumour interaction?Clin. Nutr.26(6), 667–676 (2007).
   PubMed Web of Science ®Google Scholar
• Evans WJ , MorleyJE, ArgilésJet al.: Cachexia: a new definition.Clin. Nutr.27(6), 793–799 (2008).
   PubMed Web of Science ®Google Scholar
• Knoll S , ZimmerS, HinneyA, ScheragA, NeubauerA, HebebrandJ: Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia.BMC Cancer8, 85 (2008).
   PubMed Web of Science ®Google Scholar
• Narayanan R , MohlerML, BohlCE, MillerDD, DaltonJT: Selective androgen receptor modulators in preclinical and clinical development.Nucl. Recept. Signal.6, E010 (2008).
   PubMedGoogle Scholar
• Costelli P , MuscaritoliM, BossolaMet al.: IGF-1 is downregulated in experimental cancer cachexia.Am. J. Physiol. Regul. Integr. Comp. Physiol.291(3), R674–R683 (2006).
   PubMed Web of Science ®Google Scholar
• Esper DH , HarbWA: The cancer cachexia syndrome: a review of metabolic and clinical manifestations.Nutr. Clin. Pract.20(4), 369–376 (2005).
   PubMedGoogle Scholar
• Mattox TW : Treatment of unintentional weight loss in patients with cancer.Nutr. Clin. Pract.20(4), 400–410 (2005).
   PubMedGoogle Scholar
• Yeh S , LovittS, SchusterMW: Pharmacological treatment of geriatric cachexia: evidence and safety in perspective.J. Am. Med. Dir. Assoc.8(6), 363–377 (2007).
   PubMed Web of Science ®Google Scholar
• Negro-Vilar A : Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium.J. Clin. Endocrinol. Metab.84(10), 3459–3462 (1999).
   PubMed Web of Science ®Google Scholar
• Matsumoto T , TakeyamaK, SatoT, KatoS: Study of androgen receptor functions by genetic models.J. Biochem.138(2), 105–110 (2005).
   PubMed Web of Science ®Google Scholar
• Narayanan R , CossCC, YepuruM, KearbeyJD, MillerDD, DaltonJT: Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways.Mol. Endocrinol.22(11), 2448–2465 (2008).
   PubMed Web of Science ®Google Scholar
• Fang H , TongW, BranhamWSet al.: Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor.Chem. Res. Toxicol.16(10), 1338–1358 (2003).
   PubMed Web of Science ®Google Scholar
• Ting H , ChangC: Actin associated proteins function as androgen receptor coregulators: an implication of androgen receptor’s roles in skeletal muscle.J. Steroid Biochem. Mol. Biol.111(3–5), 157–163 (2008).
   PubMed Web of Science ®Google Scholar
• Harle L , BasariaS, DobsAS: Androgens, anabolic steroids and glucocorticoids. In: Pharmacotherapy of cachexia.HofbauerK, AnkerS, InuiA, NicholsonJR (Eds). CRC/Taylor & Francis, FL, USA, 325–346 (2006).
   Google Scholar
• Boughton B : Drug increases lean tissue mass in patients with cancer.Lancet Oncol.4(3), 135 (2003).
   PubMed Web of Science ®Google Scholar
• Barqawi AB , CrawfordED: Testosterone replacement therapy and the risk of prostate cancer: a perspective view.Int. J. Impot. Res.17(5), 462–463 (2005).
   PubMed Web of Science ®Google Scholar
• Wang C , CunninghamG, DobsAet al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.J. Clin. Endocrinol. Metab.89(5), 2085–2098 (2004).
   PubMed Web of Science ®Google Scholar
• Dalton JT , MukherjeeA, ZhuZ, KirkovskyL, MillerDD: Discovery of nonsteroidal androgens.Biochem. Biophys. Res. Commun.244(1), 1–4 (1998).
   PubMed Web of Science ®Google Scholar
• Gao W , DaltonJT: Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).Drug Discov. Today12(5–6), 241–248 (2007).
   PubMed Web of Science ®Google Scholar
• Kuil CW , BerrevoetsCA, MulderE: Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization.J. Biol. Chem.270(46), 27569–27576 (1995).
   PubMed Web of Science ®Google Scholar
• Bhasin S , JasujaR: Selective androgen receptor modulators as function promoting therapies.Curr. Opin. Clin. Nutr. Metab. Care12(3), 232–240 (2009).
   PubMed Web of Science ®Google Scholar
• Yin D , GaoW, KearbeyJDet al.: Pharmacodynamics of selective androgen receptor modulators.J. Pharmacol. Exp. Ther.304(3), 1334–1340 (2003).
   PubMed Web of Science ®Google Scholar
• Jordan VC : Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer.Br. J. Pharmacol.147(Suppl. 1), S269–S276 (2006).
   PubMedGoogle Scholar
• Chen J , KimJ, DaltonJT: Discovery and therapeutic promise of selective androgen receptor modulators.Mol. Interv.5(3), 173–188 (2005).
   PubMedGoogle Scholar
• Mohler ML , NairVA, HwangDJ, RakovIM, PatilR, MillerDD: Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates.Expert Opin. Ther. Pat.15(11), 1565–1585 (2005).
   Web of Science ®Google Scholar
• Gao W , KearbeyJD, NairVAet al.: Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5α-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.Endocrinology145(12), 5420–5428 (2004).
   PubMed Web of Science ®Google Scholar
• Andriole G , BruchovskyN, ChungLWet al.: Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia.J. Urol172(4 Pt 1), 1399–1403 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson IM , GoodmanPJ, TangenCMet al.: The influence of finasteride on the development of prostate cancer.N. Engl. J. Med.349(3), 215–224 (2003).
   PubMed Web of Science ®Google Scholar
• Basaria S , DobsAS: New modalities of transdermal testosterone replacement.Treat. Endocrinol.2(1), 1–9 (2003).
   PubMedGoogle Scholar
• Marhefka CA , GaoW, ChungKet al.: Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators.J. Med. Chem.47(4), 993–998 (2004).
   PubMed Web of Science ®Google Scholar
• Segal S , NarayananR, DaltonJT: Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery.Expert Opin. Investig. Drugs15(4), 377–387 (2006).
   PubMed Web of Science ®Google Scholar
• Kuuranne T , LeinonenA, SchanzerW, KamberM, KostiainenR, ThevisM: Aryl-propionamide-derived selective androgen receptor modulators: liquid chromatography-tandem mass spectrometry characterization of the in vitro synthesized metabolites for doping control purposes.Drug Metab. Dispos.36(3), 571–581 (2008).
   PubMed Web of Science ®Google Scholar
• Kearbey JD , WuD, GaoW, MillerDD, DaltonJT: Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator.Xenobiotica34(3), 273–280 (2004).
   PubMed Web of Science ®Google Scholar
• Gao W , ReiserPJ, CossCCet al.: Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats.Endocrinology146(11), 4887–4897 (2005).
   PubMed Web of Science ®Google Scholar
• Kearbey JD , GaoW, NarayananRet al.: Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats.Pharm Res.24(2), 328–335 (2007).
   PubMed Web of Science ®Google Scholar
• Morton RA Jr , BarnetteKG, HancockML, RodriguezD, DaltonJT, SteinerMS: The use of a selective androgen receptor modulator to improve lean body mass and muscle performance in patients with cancer cachexia. Proceedings of the 91st Endocrine Society’s Annual Meeting ENDO 09.Washington, DC, USA (2009).
   Google Scholar
• Thevis M , KamberM, SchanzerW: Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes.Rapid Commun. Mass Spectrom.20(5), 870–876 (2006).
   PubMed Web of Science ®Google Scholar
• Maltoni M , NanniO, ScarpiE, RossiD, SerraP, AmadoriD: High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials.Ann. Oncol.12(3), 289–300 (2001).
   PubMed Web of Science ®Google Scholar
• Pascual López A , Roqué i FigulsM, Urrútia CuchiGet al.: Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome.J. Pain Symptom Manage.27(4), 360–369 (2004).
   PubMed Web of Science ®Google Scholar
• Jatoi A , WindschitlHE, LoprinziCLet al.: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A north central cancer treatment group study.J. Clin. Oncol.20(2), 567–573 (2002).
   PubMed Web of Science ®Google Scholar
• Martin BR , WileyJL: Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.J. Support Oncol.2(4), 305 –314; discussion 314–316 (2004).
   PubMedGoogle Scholar
• Wooldridge JE , AndersonCM, PerryMC: Corticosteroids in advanced cancer.Oncology (Williston Park)15(2), 225–234; discussion 234–236 (2001).
   PubMed Web of Science ®Google Scholar
• Loprinzi CL , KuglerJW, SloanJAet al.: Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.J. Clin. Oncol.17(10), 3299–3306 (1999).
   PubMed Web of Science ®Google Scholar
• Mercadante S , FulfaroF, CasuccioA: The use of corticosteroids in home palliative care.Support Care Cancer9(5), 386–389 (2001).
   PubMed Web of Science ®Google Scholar
• Kardinal CG , LoprinziCL, SchaidDJet al.: A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia.Cancer65(12), 2657–2662 (1990).
   PubMed Web of Science ®Google Scholar
• Davis MP , KhawamE, PozueloL, LagmanR: Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project.Expert Rev. Anticancer Ther.2(4), 365–376 (2002).
   PubMedGoogle Scholar
• Bruera E , StrasserF, PalmerJLet al.: Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study.J. Clin. Oncol.21(1), 129–134 (2003).
   PubMed Web of Science ®Google Scholar
• Fearon KC , Von MeyenfeldtMF, MosesAGet al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial.Gut52(10), 1479–1486 (2003).
   PubMed Web of Science ®Google Scholar
• Khan ZH , SimpsonEJ, ColeATet al.: Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass.Aliment. Pharmacol. Ther.17(5), 677–682 (2003).
   PubMed Web of Science ®Google Scholar
• Goldberg RM , LoprinziCL, MailliardJAet al.: Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.J. Clin. Oncol.13(11), 2856–2859 (1995).
   PubMed Web of Science ®Google Scholar
• Hyltander A , KornerU, LundholmKG: Evaluation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours.Eur. J. Clin. Invest.23(1), 46–52 (1993).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT , HerroldJ, AliIet al.: Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer.Cancer58(1), 183–186 (1986).
   PubMed Web of Science ®Google Scholar
• Yavuzsen T , DavisMP, WalshDet al.: Systematic review of the treatment of cancer-associated anorexia and weight loss.J. Clin. Oncol.23(33), 8500–8511 (2005).
   PubMed Web of Science ®Google Scholar
• Gao W , KimJ, DaltonJT: Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands.Pharm. Res.23(8), 1641–1658 (2006).
   PubMed Web of Science ®Google Scholar

Websites

• SEER Cancer Statistics Review 1975–2006 [Internet] National Cancer Institute, MD, USA (2009). http://seer.cancer.gov/csr/1975_2006/
   Google Scholar
• GTx announces investigational Ostarine™ (MK-2866) met the primary end point in the Phase II cancer cachexia clinical trial: GTx, Inc. (2008). http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle&ID=1208524&highlight=
   Google Scholar
• MK-2866 (Ostarine): Aiming to build muscle in the elderly and in cancer patients to enhance QoL and treatment outcomes: GTx, Inc. (2009). www.gtxinc.com/Pipeline/OstarineMK2866.aspx?Sid=4.
   Google Scholar
• GTx, Inc. initiates Phase II clinical trial of Ostarine, a first-in-class drug: GTx, Inc. (2006). http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle&ID=856430&highlight=
   Google Scholar
• GTx announces that Ostarine achieved primary end point of lean body mass and a secondary end point of improved functional performance in a Phase II clinical trial and reacquisition of full rights to GTx SARM Program, www.gtxinc.com: GTx, Inc. (2006). http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle&ID=940363&highlight=
   Google Scholar
• GTx announces Ostarine improved insulin resistance among elderly patients in a recently completed Phase II clinical trial: GTx, Inc. (2007). http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle&ID=985744&highlight=
   Google Scholar
• World Anti-Doping Agency Prohibited List (2009). www.wada-ama.org/en/prohibitedlist.ch2
   Google Scholar